Strategic Collaboration Sample Clauses

Strategic Collaboration. The YES program has built strong relationships with numerous agencies across the Durham community in order to better serve the youth enrolled in services. In addition to our continuing partners, the FYO and Fostering Wellness project will significantly expand the program's collaborative work in 2016. • Community Empowerment Fund • Community Partnerships, Inc. • Dress for Success Triangle • Durham Technical Community College • Genesis Home • Life Skills Foundation • PLM Families Together, Inc. • Wake Technical Community College • Youth Villages • United Way of the Greater Triangle • LINKS Program • Second Family Foundation • Inter-Faith Food Shuttle • LIFE Skills Foundation • SaySo • The Hope Center at Xxxxxx • GSK Recognizing the limitations of WIOA resources, YES will continue to build these relationships in program year 2016 and will strategically target new partners to meet the needs of the young people we serve. Durham YES & Achievement Academy of Durham The Achievement Academy of Durham and the YES program have established a strong and effective partnership, one that drives referrals for both programs and that helps youth achieve educational success. When a YES participant requires GED classes, staff members from the Achievement Academy participate in that youth’s initial ISS meeting along with the YES Youth Specialist. Together, they help the youth establish realistic and achievable benchmarks for earning a GED and identify the supportive services he or she will need in place in order to be successful. Staff from both organizations will help the youth understand what to expect from GED classes and set clear expectations for participation. Some of the young people who have earned their GEDs through the Achievement Academy and are pursuing their post-secondary education have gone on to provide tutoring to their peers enrolled in GED classes. YES and the Achievement Academy also hold monthly clinical team meetings, at which they discuss the progress of the youth enrolled in both programs and develop action steps for addressing problems or concerns.
AutoNDA by SimpleDocs
Strategic Collaboration. This protocol is designed to work alongside and not separately from, existing processes in each organisation and, where relevant, reflects these for the benefit of staff and management. The persons in each organisation responsible for the MoU will oversee the application of the protocol. The protocol is not time limited and will continue to have effect unless any section needs to be altered or ceases to be relevant.
Strategic Collaboration. Strategic collaboration includes longer term, higher level activity such as national concerns, thematic reviews, and media and communications work. This work strand is primarily managed by both organisations through the strategic contacts listed in Appendix 1 to this protocol.
Strategic Collaboration. The Durham YES program has built a strong network of collaborative partners in its five years of operation to access referrals and link enrolled youth to WIA services identified on their individual service strategies. These include, but are not limited to: o City of Durham o Achievement Academy of Durham o Gateway to College o The Edge Program o Milestones Culinary Arts Institute o Durham Tech. Community College o Teen Literacy Center o Carolina Outreach o N.C. Division of Vocational Rehabilitation o Department of Social Services o Durham Housing Authority o Durham Parks & Recreation o Durham Juvenile Justice Crime Prevention Council o Durham Public Schools o Durham Alliance of Childcare Access o Lincoln Health Clinic o Welcome Baby o Sales and Service Training Center o Performance Learning Center Recognizing the limitations of WIA resources, YES will continue to build these relationships in program year 2011 and will strategically target new partners to meet the needs of the young people we serve.
Strategic Collaboration. The Durham YES program has built a strong network of collaborative partners over the past seven program years to access referrals and link enrolled youth to WIA services identified on their individual service strategies. These include, but are not limited to: o City of Durham o Achievement Academy of Durham o Durham Technical Community College o Durham Public Schools o Gateway to College o The Durham Center o N.C. Division of Vocational Rehabilitation o Department of Social Services o Durham Housing Authority o Durham Parks & Recreation o Durham Juvenile Justice Crime Prevention Council o Durham Alliance of Childcare Access o Welcome Baby o CAARE, Inc. o Pregnancy Support Services o Building a Better You Program o Milestones Culinary Arts Institute o Pinnacle Culinary Arts o Gericare o JPD Research o Optimal Health College o Sales and Service Training Center o Ark of Safety Education and Training Program o Durham Performance Learning Center o Durham Literacy Center o The Edge Program Recognizing the limitations of WIA resources, YES will continue to build these relationships in program year 2012 and will strategically target new partners to meet the needs of the young people we serve.
Strategic Collaboration. The Durham YES program has built a strong network of collaborative partners in its 10 years of operation. We will continue to work with our partner agencies in the coming program year, but have also identified five key areas in which we will work to strengthen and expand collaborative efforts.
Strategic Collaboration. ‌ Introducing USAID Yidgiri to and consulting with other RISE II implementing partners and stakeholders on possible areas of synergy were a major focus for the leadership during the Refine and Implement period. As a result, MOUs and formal collaborations were signed and established with strategic organizations that have common or shared objectives. During FY21, Yidgiri will continue to strengthen these linkages and coordinate efforts with USAID and non- USAID funded programs in Burkina Faso for efficient implementation and greater impact.
AutoNDA by SimpleDocs
Strategic Collaboration. Having regard to the objectives set forth in Section 2.1, the Parties hereby agree that:
Strategic Collaboration 

Related to Strategic Collaboration

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.